FinTechFunding

Neuren Pharmaceuticals: Receives US$10m milestone payment

Neuren Pharmaceuticals Receives US$10m milestone payment

  • Neuren Pharmaceuticals (NEU) receives a US$10 million (A$16 million) milestone payment from its partner, Acadia Pharmaceuticals
  • The payment follows the US FDA’s acceptance for review of Acadia’s new drug application for trofinetide, which works to treat Rett syndrome
  • Acadia has exclusive rights to develop and commercialise trofinetide in North America, while Neuren holds all rights to the treatment outside of this
  • If the new drug application (NDA) is approved by the FDA, the next potential milestone payment to Neuren would be US$40 million (A$62 million), which would be payable following the first commercial sale of trofinetide in the United States
  • NeurenPharmaceuticals dips 0.13 per cent to trade at $7.51 at 1:00 pm AEDT
Previous article
Nucleome Therapeutics: Raises £37.5M in Series A Financing
Next article
DroneShield: Completes delivery of $1.8m contract
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa Unveils Tool to Strengthen Agentic Commerce for Firms

New offering aims to simplify and enhance digital commerce capabilities. Highlights: Visa launches a new tool for agentic commerce.The...
FinTech

AI Citing Bolt Lays Off a Third of Staff

The tech company streamlines operations amidst shifting market conditions. Highlights: Bolt reduces workforce by a third due to AI...
FinTech

MillTech Secures $60 Million to Expand into US Market

Funding positions MillTech for growth in North America. Highlights: MillTech raises $60 million for US expansion.The funding aims to...
FinTech

KreditBee Joins Unicorn Club After $280 Million Funding Round

Fintech firm KreditBee reaches unicorn status with significant investor backing. Highlights: KreditBee raises $280 million in Series D funding.Company...